LEGN
Legend Biotech Corporation
$34.73
+$0.36(+1.05%)
53
Overall
--
Value
50
Tech
57
Quality
Market Cap
$6.44B
Volume
881.55K
52W Range
$27.34 - $59.62
Target Price
$78.24
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $57.3M | $75.7M | $89.8M | $116.7M | $285.0M | $621.0M | ||
| Total Revenue | $59.4M | $78.8M | $91.9M | $117.0M | $285.1M | $627.2M | ||
| COST OF GOODS SOLD | ||||||||
| Cost of Revenue | -- | -- | -- | $-65.4M | $144.2M | $234.6M | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $59.4M | $78.8M | $91.9M | $51.6M | $140.9M | $392.7M | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $194.4M | $305.2M | $472.0M | $-416.3M | $553.5M | $529.2M | ||
| Research & Development | $161.9M | $232.2M | $313.3M | $-335.6M | $382.2M | $413.5M | ||
| Research Expense | $161.9M | $232.2M | $313.3M | $-335.6M | $382.2M | $413.5M | ||
| Selling, General & Administrative | $32.2M | $72.7M | $149.5M | $-80.6M | $200.9M | $288.7M | ||
| Selling & Marketing Expenses | $25.6M | $49.6M | $102.5M | -- | $94.2M | $147.5M | ||
| General & Administrative Expenses | $6.6M | $23.1M | $46.9M | $-80.6M | $106.8M | $141.2M | ||
| Salaries & Wages | -- | $-4.8M | -- | $-34.3M | -- | -- | ||
| Depreciation & Amortization | -- | $346.0K | -- | $-10.2M | -- | -- | ||
| Depreciation & Amortization | -- | $346.0K | -- | $-10.2M | -- | -- | ||
| Amortization | -- | $346.0K | -- | -- | -- | -- | ||
| Other Operating Expenses | $221.0K | $346.0K | $9.1M | $-1.3M | $-29.6M | $-173.1M | ||
| OPERATING INCOME | ||||||||
| Operating income | $-135.0M | $-226.4M | $-380.1M | $-365.0M | $-412.6M | $-136.5M | ||
| EBITDA | -- | $-298.2M | -- | $-416.5M | $-477.9M | $-113.2M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | $199.0K | $195.0K | $900.0K | $10.8M | $21.8M | $21.6M | ||
| Interest Income Operating | $4.6M | $2.9M | $971.0K | -- | $54.5M | -- | ||
| Intinc | -- | $2.9M | -- | $8.2M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-199.0K | $-195.0K | $-900.0K | $-9.8M | $-21.8M | $-21.6M | ||
| Other Income/Expense | -- | $4.0M | -- | $-61.5M | $85.8M | -- | ||
| Other Special Charges | -- | $-4.0M | -- | $10.7M | $3.6M | -- | ||
| SPECIAL ITEMS | ||||||||
| Special Income Charges | -- | $-80.0M | $-6.2M | -- | -- | -- | ||
| Impairment of Capital Assets | -- | $-22.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||
| EBIT | -- | $-308.1M | -- | $-434.9M | $-498.3M | $-136.5M | ||
| Pre-Tax Income | $-130.3M | $-307.6M | $-386.2M | $-436.2M | $-520.1M | $-158.1M | ||
| INCOME TAX | ||||||||
| Tax Provision | $-2.6M | $-4.1M | $1.0K | $625.0K | $1.9M | $18.9M | ||
| NET INCOME | ||||||||
| Net Income | $-127.7M | $-303.5M | $-386.2M | $-446.3M | $-522.0M | $-177.0M | ||
| Net Income (Continuing Operations) | $-127.7M | $-303.5M | $-386.2M | $-436.9M | $-522.0M | $-177.0M | ||
| Net Income (Discontinued Operations) | $-127.7M | $-303.5M | $-386.2M | $-446.3M | $-522.0M | $-177.0M | ||
| Net Income (Common Stockholders) | $-127.7M | $-303.5M | $-386.2M | $-446.3M | $-522.0M | $-177.0M | ||
| Normalized Income | -- | -- | -- | -- | $-382.3M | $-156.6M | ||
| TOTALS | ||||||||
| Total Expenses | -- | $255.7M | -- | $350.9M | $697.7M | $763.8M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $100.0M | $118.2M | $137.1M | $318.1M | $352.2M | $182.9M | ||
| Average Shares Outstanding (Diluted) | $100.0M | $56.9M | $137.1M | $312.1M | $352.2M | $182.9M | ||
| Shares Outstanding | $183.6M | $266.0M | $183.6M | $330.1M | $183.6M | $183.6M | ||
| Basic EPS | -- | $-2.56 | $-2.74 | $-1.4 | $-1.47 | $-0.96 | ||
| Basic EPS (Continuing Operations) | -- | $-2.56 | $-2.74 | -- | $-1.47 | $-0.96 | ||
| Diluted EPS | -- | $-2.56 | $-2.74 | $-1.4 | $-1.47 | $-0.96 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.56 | $-2.74 | -- | $-1.47 | $-0.96 | ||
| OTHER METRICS | ||||||||
| Allowances For Construction | -- | $-30.4M | -- | $-60.5M | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | $9.8M | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | $144.2M | $234.6M | ||
| Other Gand A | $6.6M | $23.1M | $46.9M | $-80.6M | $106.8M | $141.2M | ||
| Other Impairment Of Capital Assets | -- | $4.2M | -- | -- | -- | -- | ||
| Other Write Off | -- | -- | -- | $10.8M | -- | -- | ||
| Realized Capital Gain | -- | $-2.1M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-138.0K | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | $80.0M | $6.2M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LEGN | $34.73 | +1.0% | 881.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Legend Biotech Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW